The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M

Tseng J.-S.KANG-YI SUYang T.-Y.Chen K.-C.Hsu K.-H.Chen H.-Y.Tsai C.-R.SUNG-LIANG YUChang G.-C.2020-06-302020-06-3020161949-2553https://scholars.lib.ntu.edu.tw/handle/123456789/507234Different growth kinetics occurring between the sensitive and T790M-containing cells may result in the repopulation of tumor cells over time. Little information has yet been uncovered on whether rebiopsy timing influences the T790M detection rate. We enrolled a total of 98 epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients, who had a history of acquired resistance to EGFR-tyrosine kinase inhibitor (TKI) and available rebiopsy tumor specimens for reassessment of EGFR mutations. Rebiopsy was performed at the time of first EGFR-TKI progression in 54 patients (55.1%); for the other 44 patients (44.9%), rebiopsy was done with an interval from first EGFR-TKI progression (median 470.5 days, range 46-1742 days). Our results indicated that rebiopsy timing did not influence the detection rate of T790M and that the mutation could be identified in patients with a long EGFR-TKIfree interval. For patients without suitable lesions for rebiopsy at the time of EGFRTKI progression, an attempt to rebiopsy should be considered during the subsequent treatment courses.[SDGs]SDG3afatinib; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; methionine; osimertinib; threonine; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; adult; amino acid substitution; Article; cancer patient; cancer resistance; controlled study; cytopathology; female; histopathology; human; human tissue; lung adenocarcinoma; lung biopsy; lung rebiopsy; major clinical study; male; mutational analysis; progression free survival; survival time; time to treatment; treatment response; adenocarcinoma; aged; antagonists and inhibitors; biopsy; disease exacerbation; drug resistance; enzymology; genetics; lung tumor; middle aged; mutation; pathology; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Receptor, Epidermal Growth FactorThe emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790Mjournal article10.18632/oncotarget.10351273844802-s2.0-84982802734